Theravance Biopharma, Inc. (TBPH) is a publicly traded Healthcare sector company. As of May 21, 2026, TBPH trades at $16.55 with a market cap of $838.25M and a P/E ratio of 7.31. TBPH moved +1.72% today. Year to date, TBPH is -10.15%; over the trailing twelve months it is +75.13%. Its 52-week range spans $7.88 to $21.03. Analyst consensus is buy with an average price target of $16.61. Rallies surfaces TBPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for TBPH shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $16.55 |
| Market Cap | $838.25M |
| P/E Ratio | 7.31 |
| EPS | $2.26 |
| Dividend Yield | 0.00% |
| 52-Week High | $21.03 |
| 52-Week Low | $7.88 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $109.78M |
| Net Income | $114.54M |
| Gross Margin | 0.00% |
6 analysts cover TBPH: 0 strong buy, 3 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $16.61.